Novel Modalities,
Transformative Outcomes

- Phase II program efficacious in Claudin 18.2 ultra-low expressors

- CD73 oral small molecule inhibitor with robust PoC data in reversing anti-PD-1 resistance

- Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicity

- First-in-class macrophage activator targeting CD24 expressing solid tumors

Our Approach

Our Approach

NextGen Novel Immuno-oncology and Targeted Drugs – Allowing Broad Proprietary Combinations

Tumor Microenvironment

Tumor Cell

  • ATN-022

    (Claudin 18.2 ADC)

    High-affinity antibody allowing the targeting of Claudin 18.2 low expressors
  • ATN-037

    (CD73 Small Molecule Inhibitor)

    Robust PoC data demonstrated ability in reversing anti-PD-1 resistance
  • ATN-101 (Xirestomig)

    (PD-L1/4-1BB Bispecific Antibody)

    Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicities
  • ATN-031

    (CD24 Monoclonal Antibody)

    Novel macrophage activator targeting CD24-expressing solid tumors

Clinical Pipeline

Validated and Transformational Clinical Programs

Assets
Target
(Modality)
IND
Phase I
Phase II
De-risked Programs Supported by PoC Data
Claudin 18.2
(ADC)
CLINCH
CD73
(Small Molecule)
STAMINA
Transformational Assets
PD-L1/4-1BB
(BsAb)
PROBE
CD24
(mAb)
PERFORM
Assets
Target
(Modality)
IND
Phase I
Phase II
De-risked Programs Supported by PoC Data

ATN-022

Claudin 18.2
(ADC)

CLINCH

ATN-037

CD73
(Small Molecule)

STAMINA
Transformational Assets

ATN-101
(Xirestomig)

PD-L1/4-1BB
(BsAb)

PROBE

ATN-031

CD24
(mAb)

PERFORM
Ongoing Trials

Strategic Pipeline with De-risked, Differentiated Programs and High-value Clinical Programs

ATN-022
ATN-037
ATN-101 (Xirestomig)
ATN-031
Target and Modality
Claudin 18.2 ADC
CD73 Small Molecule
PD-L1/4-1BB Bispecific Antibody
CD24 Monoclonal Antibody
Target Unmet Medical Needs
Claudin 18.2 Expressing tumors

(Claudin 18.2 Low/High Expression Gastric Cancer and Other Solid Tumors)
Checkpoint inhibitor (CPI)-resistant tumors

(Non-small Cell Lung Cancer and Melanoma)
Immune-responsive Tumors (e.g, Melanoma) and "Cold" Tumors

(e.g, Colorectal Cancer)
CD24 Expressing Tumors

(Breast Cancer, Ovarian Cancer, Small Cell Lung Cancer, Non-small Cell Lung Cancer, Liver Cancer, Bladder Cancer, B Cell Lymphoma)
Differentiation
High-affinity antibody allowing the targeting of Claudin 18.2 low expressors

Robust PoC data demonstrated ability in reversing prior anti-PD-1 resistance
Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicities
Novel macrophage activator targeting CD24 expressing solid tumors
ATN-022
Target and Modality
Claudin 18.2 ADC
Target Unmet Medical Needs
Claudin 18.2 Expressing tumors
(Claudin 18.2 Low/High Expression Gastric Cancer and Other Solid Tumors)
Differentiation
High-affinity antibody allowing the targeting of Claudin 18.2 low expressors
ATN-037
Target and Modality
CD73 Small Molecule
Target Unmet Medical Needs
Checkpoint inhibitor (CPI)-resistant tumors
(Non-small Cell Lung Cancer and Melanoma)
Differentiation
Robust PoC data demonstrated ability in reversing prior anti-PD-1 resistance
ATN-101 (Xirestomig)
Target and Modality
PD-L1/4-1BB Bispecific Antibody
Target Unmet Medical Needs
Immune-responsive Tumors (e.g, Melanoma)
and "Cold" Tumors (e.g, Colorectal Cancer)
Differentiation
Bispecific antibody targeting PD-L1/4-1BB overcoming liver toxicities
ATN-031
Target and Modality
CD24 Monoclonal Antibody
Target Unmet Medical Needs
CD24 Expressing Tumors
(Breast Cancer, Ovarian Cancer, Small Cell Lung Cancer, Non-small Cell Lung Cancer, Liver Cancer, Bladder Cancer, B Cell Lymphoma)
Differentiation
Novel macrophage activator targeting CD24 expressing solid tumors

Antennova Team

Jay Mei, M.D., Ph.D.
Founder / Interim CEO

Pennsylvania, US

Ariel Guo
Chief Operating Officer

Boston, MA, US

Donald Lung, JD, MBA
Interim Chief Financial Officer

Nadeem Mirza, M.D., MPH
Senior Clinical Expert

Houston, US

Sunny He
Senior Director, Clinical Operations

Bingshan Liu, M.D., Ph.D.
Associate Medical Director

Jon Yau
Investor Relations Manager

Board of Directors

Jay Mei, M.D., Ph.D.
Executive Chairman of the Board

Donald Lung, JD, MBA
Executive Director

Anne Altmeyer, Ph.D., MBA, MPH
Independent Non-executive Director

Selwyn Ho, MBBS, B.Sc
Independent Non-executive Director

Strategic Advisor

Shawn Leland, PharmD, RPh
Strategic Advisor

News

Contact Us